<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927080</url>
  </required_header>
  <id_info>
    <org_study_id>A083-02</org_study_id>
    <secondary_id>ACE-083</secondary_id>
    <nct_id>NCT02927080</nct_id>
  </id_info>
  <brief_title>Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study A083-02 is a multicenter, Phase 2 study to evaluate the safety, tolerability,
      pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE 083 in patients with FSHD
      to be conducted in two parts. Part 1 is open-label, dose-escalation and Part 2 is randomized,
      double-blind, and placebo-controlled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 (dose escalation, open-label) Part 1 will consist of up to 6 cohorts (A to F) of
      patients and will evaluate multiple ascending dose levels of ACE-083 in either the tibialis
      anterior (TA) or biceps brachii (BB) muscle. Patients in each cohort will be enrolled in a
      4-week screening period before beginning treatment. A Safety Review Team (SRT) will meet to
      review data for each cohort when at least 4 patients within a cohort have completed their Day
      43 visit prior to dose escalation.

      Part 2 (randomized, double-blind, placebo-controlled, with open-label extension) Prior to the
      initiation of Part 2, a review of safety and efficacy data from Part 1 will be conducted to
      determine whether cohorts for one or both muscles will be pursued in Part 2, as well as the
      recommended dose level for each muscle. A total of up to 56 new patients (28 patients per
      muscle) may be enrolled and randomized (1:1) to receive either ACE-083 (n=14/muscle) or
      placebo (n=14/muscle) bilaterally to either the TA or BB muscles (but not both). Patients
      will receive blinded study drug once every three weeks for approximately 6 months (9 doses).

      Patients who complete the double-blind treatment period will immediately roll over to
      open-label treatment with ACE-083, receiving the same dose of active drug, bilaterally in
      either the TA or BB muscle, once every three weeks for approximately 6 months (8 doses). In
      Part 2, the SRT will periodically review blinded safety data for each muscle treated.

      Study duration for Part 1 for each patient will be approximately 24 weeks, including a 4-week
      screening period, a 12-week treatment period, and an 8-week follow-up period after the last
      dose.

      Study duration for Part 2 for each patient will be approximately 15 months, including a
      1-month screening period, a 12-month treatment period (6-month double-blind,
      placebo-controlled and a 6-month open-label extension), and a 2-month follow-up period after
      the last dose
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigation of ACE-083 for use in patients with FSHD is being discontinued as it did not
    achieve functional secondary endpoints in the A083-02 trial.
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">October 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability (data collection on the incidence, nature and severity of adverse events).</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141).</time_frame>
    <description>Adverse events will be recorded and coded in accordance with MedDRA v.20,0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of systemic exposure to ACE-083 following local intramuscular administration.</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141).</time_frame>
    <description>Bioanlaytical assay for the quantitative of ACE-083 in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in strength of injected muscle</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of treatment visit.</time_frame>
    <description>Strength measurements by hand-held or fixed-system dynamometry (quantitative muscle testing).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in function of injected muscle</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141).</time_frame>
    <description>Function assessed by a battery of motor function tests; 4-stair climb, 6-minute walk test, gait analysis and performance of the upper limb (PUL) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient-reported outcome (PRO) measures</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141).</time_frame>
    <description>PRO assessed by health-related quality of life and disease burden, as measured by the FSHD Health Index questionnaire (FSHD-HI).</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>ACE-083 (Part 1, Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 150 mg IM, once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083 (Part 1, Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 200 mg IM, once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083 (Part 1, Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 up to 250 mg IM, once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083 (Part 2, DB-PC, IM tibialis anterior muscle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083 (Part 2, PL, IM tibialis anterior muscle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-Label ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083, (Part 2, DB-PC, IM biceps brachii muscle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (biceps brachii muscle) or placebo, once every 3 weeks for up to 9 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-083 (Part 2, OP, biceps brachii muscle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-Label ACE-083 up to 250 mg IM (biceps brachii muscle), once every 3 weeks for up to 8 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-083</intervention_name>
    <description>Recombinant fusion protein.</description>
    <arm_group_label>ACE-083 (Part 1, Cohort 1)</arm_group_label>
    <arm_group_label>ACE-083 (Part 1, Cohort 2)</arm_group_label>
    <arm_group_label>ACE-083 (Part 1, Cohort 3)</arm_group_label>
    <arm_group_label>ACE-083 (Part 2, OP, biceps brachii muscle)</arm_group_label>
    <arm_group_label>ACE-083 (Part 2, PL, IM tibialis anterior muscle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-083 or placebo</intervention_name>
    <description>Recombinant fusion protein or normal saline.</description>
    <arm_group_label>ACE-083 (Part 2, DB-PC, IM tibialis anterior muscle)</arm_group_label>
    <arm_group_label>ACE-083, (Part 2, DB-PC, IM biceps brachii muscle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥ 18 years

          2. Genetically-confirmed FSHD1 or FSHD2 (or a first-degree relative with genetically
             confirmed FSHD1 or FSHD2) and clinical findings meeting FSHD criteria

          3. Part 1 TA cohorts:

               1. 6-minute walk distance (6MWD) ≥ 150 meters (without a brace)

               2. Mild to moderate weakness in left and/or right ankle dorsiflexion

             Part 1 BB cohorts:

             a. Mild to moderate weakness in left and/or right elbow flexion

             Part 2 TA cohorts:

               1. 6MWD ≥ 150 and ≤ 500 meters (without a brace)

               2. Mild to moderate weakness in left and right ankle dorsiflexion

             Part 2 BB cohorts:

             a. Mild to moderate weakness in left and/or right elbow flexion

          4. Females of childbearing potential must have negative urine pregnancy test prior to
             enrollment and use highly effective birth control methods during study participation.
             Hormonal birth control use must be stable for at least 14 days prior to Day 1. Males
             must agree to use a condom during any sexual contact with females of childbearing
             potential while participating in the study even if he has undergone a successful
             vasectomy.

        Key Exclusion Criteria:

          1. Current/ active malignancy (e.g., remission less than 5 years duration), with the
             exception of fully excised or treated basal cell carcinoma, cervical carcinoma
             in-situ, or ≤ 2 squamous cell carcinomas of the skin

          2. Symptomatic cardiopulmonary disease, significant functional impairment, or other co
             morbidities that in the opinion of the investigator would limit a patient's ability to
             complete strength and/or functional assessments on study

          3. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal [ULN])

          4. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN

          5. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any
             anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1; low
             dose aspirin [≤ 100 mg daily] is permitted)

          6. Major surgery within 4 weeks prior to Study Day 1

          7. Chronic systemic corticosteroids (≥ 2 weeks) within 4 weeks before Study Day 1 and for
             duration of study; intra-articular/topical/inhaled therapeutic or physiologic doses of
             corticosteroids are permitted

          8. Androgens or growth hormone within 6 months before Study Day 1 and for duration of
             study; topical physiologic androgen replacement is permitted

          9. Any condition that would prevent MRI scanning or compromise the ability to obtain a
             clear and interpretable scan of the TA or BB muscles, as applicable (e.g., pacemaker,
             knee/hip replacement, or metallic implants)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hugo W. Moser Research Inst. at Kennedy Krieger Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System Neurosciences Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute &amp; Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

